036480 — Daesung Microbiological Labs Co Cashflow Statement
0.000.00%
Last trade - 00:00
- KR₩41bn
- KR₩53bn
- KR₩26bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 2,850 | 1,519 | 866 | 1,703 | -680 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 754 | 1,309 | 453 | -919 | 703 |
Accounting Change | |||||
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -2,398 | -1,539 | -1,654 | -2,335 | -4,120 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 2,315 | 3,236 | 2,203 | 1,155 | -1,234 |
Capital Expenditures | -11,575 | -14,444 | -2,969 | -2,315 | -1,260 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 1,810 | -1,128 | -672 | 1,157 | 1,496 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -9,764 | -15,572 | -3,641 | -1,158 | 236 |
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 10,695 | 9,558 | 305 | -646 | 1,481 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 3,309 | -3,040 | -817 | -543 | 511 |